- Home
- FULC vs RGR Comparison
FULC vs RGR Comparison
Compare FULC & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- RGR
- Stock Information
- Founded
- FULC 2015
- RGR 1949
- Country
- FULC United States
- RGR United States
- Employees
- FULC N/A
- RGR N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- RGR Ordnance And Accessories
- Sector
- FULC Health Care
- RGR Industrials
- Exchange
- FULC Nasdaq
- RGR Nasdaq
- Market Cap
- FULC 469.0M
- RGR 553.4M
- IPO Year
- FULC 2019
- RGR N/A
- Fundamental
- Price
- FULC $8.73
- RGR $46.30
- Analyst Decision
- FULC Buy
- RGR
- Analyst Count
- FULC 6
- RGR 0
- Target Price
- FULC $8.67
- RGR N/A
- AVG Volume (30 Days)
- FULC 524.6K
- RGR 278.3K
- Earning Date
- FULC 11-12-2025
- RGR 10-29-2025
- Dividend Yield
- FULC N/A
- RGR 1.52%
- EPS Growth
- FULC N/A
- RGR N/A
- EPS
- FULC N/A
- RGR 0.35
- Revenue
- FULC N/A
- RGR $536,291,000.00
- Revenue This Year
- FULC N/A
- RGR N/A
- Revenue Next Year
- FULC N/A
- RGR $3.39
- P/E Ratio
- FULC N/A
- RGR $133.00
- Revenue Growth
- FULC 2752.05
- RGR 3.31
- 52 Week Low
- FULC $2.32
- RGR $31.64
- 52 Week High
- FULC $9.88
- RGR $46.70
- Technical
- Relative Strength Index (RSI)
- FULC 54.66
- RGR 77.23
- Support Level
- FULC $9.10
- RGR $45.28
- Resistance Level
- FULC $9.88
- RGR $46.70
- Average True Range (ATR)
- FULC 0.57
- RGR 1.14
- MACD
- FULC -0.02
- RGR 0.09
- Stochastic Oscillator
- FULC 56.24
- RGR 89.07
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About RGR Sturm Ruger & Company Inc.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.